Ipilimumab meets NSCLC endpoint

Bristol-Myers Squibb Co. (NYSE:BMY) said both regimens of 10 mg/kg ipilimumab every

Read the full 128 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE